vs
Side-by-side financial comparison of Expeditors International (EXPD) and Viatris (VTRS). Click either name above to swap in a different company.
Viatris is the larger business by last-quarter revenue ($3.7B vs $2.9B, roughly 1.3× Expeditors International). On growth, Viatris posted the faster year-over-year revenue change (5.0% vs -3.3%). Viatris produced more free cash flow last quarter ($619.3M vs $270.3M). Over the past eight quarters, Expeditors International's revenue compounded faster (13.8% CAGR vs 0.5%).
Expeditors International of Washington, Inc. is an American Fortune 500 service-based logistics company with headquarters in Bellevue, Washington. Expeditors generates highly optimized and customized supply chain solutions for clients with unified technology systems integrated through a global network of over 340+ locations in 100+ countries on six continents.
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.
EXPD vs VTRS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.9B | $3.7B |
| Net Profit | $200.7M | — |
| Gross Margin | — | 31.1% |
| Operating Margin | 8.8% | -5.2% |
| Net Margin | 7.0% | — |
| Revenue YoY | -3.3% | 5.0% |
| Net Profit YoY | -14.9% | — |
| EPS (diluted) | $1.50 | $-0.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.9B | $3.7B | ||
| Q3 25 | $2.9B | $3.7B | ||
| Q2 25 | $2.7B | $3.6B | ||
| Q1 25 | $2.7B | $3.2B | ||
| Q4 24 | $3.0B | $3.5B | ||
| Q3 24 | $3.0B | $3.7B | ||
| Q2 24 | $2.4B | $3.8B | ||
| Q1 24 | $2.2B | $3.7B |
| Q4 25 | $200.7M | — | ||
| Q3 25 | $222.3M | — | ||
| Q2 25 | $183.6M | — | ||
| Q1 25 | $203.8M | — | ||
| Q4 24 | $235.9M | — | ||
| Q3 24 | $229.6M | — | ||
| Q2 24 | $175.5M | — | ||
| Q1 24 | $169.2M | — |
| Q4 25 | — | 31.1% | ||
| Q3 25 | — | 36.6% | ||
| Q2 25 | — | 37.3% | ||
| Q1 25 | — | 35.8% | ||
| Q4 24 | — | 34.6% | ||
| Q3 24 | — | 39.0% | ||
| Q2 24 | — | 38.2% | ||
| Q1 24 | — | 41.2% |
| Q4 25 | 8.8% | -5.2% | ||
| Q3 25 | 10.0% | 4.8% | ||
| Q2 25 | 9.3% | 6.5% | ||
| Q1 25 | 10.0% | -88.9% | ||
| Q4 24 | 10.2% | -5.1% | ||
| Q3 24 | 10.1% | 6.0% | ||
| Q2 24 | 9.2% | -6.3% | ||
| Q1 24 | 9.7% | 5.6% |
| Q4 25 | 7.0% | — | ||
| Q3 25 | 7.7% | — | ||
| Q2 25 | 6.9% | — | ||
| Q1 25 | 7.6% | — | ||
| Q4 24 | 8.0% | — | ||
| Q3 24 | 7.7% | — | ||
| Q2 24 | 7.2% | — | ||
| Q1 24 | 7.7% | — |
| Q4 25 | $1.50 | $-0.34 | ||
| Q3 25 | $1.64 | $-0.11 | ||
| Q2 25 | $1.34 | $0.00 | ||
| Q1 25 | $1.47 | $-2.55 | ||
| Q4 24 | $1.68 | $-0.43 | ||
| Q3 24 | $1.63 | $0.08 | ||
| Q2 24 | $1.24 | $-0.27 | ||
| Q1 24 | $1.17 | $0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3B | $1.3B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.4B | $14.7B |
| Total Assets | $4.9B | $37.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.3B | $1.3B | ||
| Q3 25 | $1.2B | $975.3M | ||
| Q2 25 | $1.2B | $566.4M | ||
| Q1 25 | $1.3B | $755.0M | ||
| Q4 24 | $1.1B | $734.8M | ||
| Q3 24 | $1.3B | $1.9B | ||
| Q2 24 | $1.3B | $917.2M | ||
| Q1 24 | $1.4B | $1.0B |
| Q4 25 | $2.4B | $14.7B | ||
| Q3 25 | $2.3B | $15.2B | ||
| Q2 25 | $2.2B | $15.6B | ||
| Q1 25 | $2.3B | $15.7B | ||
| Q4 24 | $2.2B | $18.6B | ||
| Q3 24 | $2.4B | $19.8B | ||
| Q2 24 | $2.2B | $19.5B | ||
| Q1 24 | $2.2B | $20.0B |
| Q4 25 | $4.9B | $37.2B | ||
| Q3 25 | $4.8B | $37.9B | ||
| Q2 25 | $4.8B | $38.4B | ||
| Q1 25 | $4.8B | $38.5B | ||
| Q4 24 | $4.8B | $41.5B | ||
| Q3 24 | $5.2B | $44.8B | ||
| Q2 24 | $4.8B | $45.3B | ||
| Q1 24 | $4.5B | $47.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $283.3M | $815.8M |
| Free Cash FlowOCF − Capex | $270.3M | $619.3M |
| FCF MarginFCF / Revenue | 9.5% | 16.8% |
| Capex IntensityCapex / Revenue | 0.5% | 5.3% |
| Cash ConversionOCF / Net Profit | 1.41× | — |
| TTM Free Cash FlowTrailing 4 quarters | $953.4M | $1.9B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $283.3M | $815.8M | ||
| Q3 25 | $201.4M | $744.9M | ||
| Q2 25 | $179.2M | $219.7M | ||
| Q1 25 | $342.6M | $535.5M | ||
| Q4 24 | $249.7M | $482.7M | ||
| Q3 24 | $90.0M | $826.5M | ||
| Q2 24 | $126.8M | $379.1M | ||
| Q1 24 | $256.9M | $614.6M |
| Q4 25 | $270.3M | $619.3M | ||
| Q3 25 | $190.3M | $658.1M | ||
| Q2 25 | $163.3M | $166.8M | ||
| Q1 25 | $329.5M | $492.9M | ||
| Q4 24 | $239.7M | $342.3M | ||
| Q3 24 | $77.7M | $749.5M | ||
| Q2 24 | $118.8M | $320.3M | ||
| Q1 24 | $246.7M | $564.8M |
| Q4 25 | 9.5% | 16.8% | ||
| Q3 25 | 6.6% | 17.6% | ||
| Q2 25 | 6.2% | 4.7% | ||
| Q1 25 | 12.4% | 15.2% | ||
| Q4 24 | 8.1% | 9.7% | ||
| Q3 24 | 2.6% | 20.1% | ||
| Q2 24 | 4.9% | 8.5% | ||
| Q1 24 | 11.2% | 15.5% |
| Q4 25 | 0.5% | 5.3% | ||
| Q3 25 | 0.4% | 2.3% | ||
| Q2 25 | 0.6% | 1.5% | ||
| Q1 25 | 0.5% | 1.3% | ||
| Q4 24 | 0.3% | 4.0% | ||
| Q3 24 | 0.4% | 2.1% | ||
| Q2 24 | 0.3% | 1.6% | ||
| Q1 24 | 0.5% | 1.4% |
| Q4 25 | 1.41× | — | ||
| Q3 25 | 0.91× | — | ||
| Q2 25 | 0.98× | — | ||
| Q1 25 | 1.68× | — | ||
| Q4 24 | 1.06× | — | ||
| Q3 24 | 0.39× | — | ||
| Q2 24 | 0.72× | — | ||
| Q1 24 | 1.52× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXPD
| Customs Brokerage And Other Services | $1.1B | 40% |
| Airfreight Services | $1.1B | 39% |
| Ocean Freight And Ocean Services | $611.4M | 21% |
VTRS
| Brands | $1.2B | 32% |
| Generics | $1.1B | 29% |
| Lipitor | $377.3M | 10% |
| Norvasc | $175.2M | 5% |
| Other | $136.6M | 4% |
| Lyrica | $119.8M | 3% |
| Viagra | $104.2M | 3% |
| Creon | $98.9M | 3% |
| Epi Pen Auto Injectors | $79.0M | 2% |
| Yupelri | $70.6M | 2% |
| Effexor | $68.1M | 2% |
| Zoloft | $66.8M | 2% |
| Celebrex | $66.2M | 2% |
| Xalabrands | $42.0M | 1% |
| Dymista | $38.6M | 1% |
